Andrew John Partridge

CIK 1758838 · Chief Growth Officer · last filed 2026-06-05

Andrew John Partridge is a Chief Growth Officer who has filed 6 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing shows the insider sold $91.1K of GRALV on Jun 5, 2026. Across all open-market trades the lifetime net is −$239.1K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$0

Companies

2

Total Filings

6

Lifetime Open-Market Net

-$239.1K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
GRAIL, Inc. (GRALV) Delisted	Chief Growth Officer	163,738	—	—	-$91.1K	1	2026-06-05
Turning Point Therapeutics, Inc. (TPTX) Delisted	EVP & Chief Commercial Officer	38,361	$76.01	$2.92M	-$148.0K	4	2022-02-11

Recent Filings

6 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-06-05	GRAIL, Inc. (GRALV) Delisted	Sell (S)	−1,491	-$91.1K	EDGAR
2026-06-03	GRAL	Notice (144)	−1,705	-$104.2K	EDGAR
2022-02-11	Turning Point Therapeutics, Inc. (TPTX) Delisted	Mixed	+16,062	-$8.0K	EDGAR
2021-07-15	Turning Point Therapeutics, Inc. (TPTX) Delisted	Sell (S)	−1,869	-$140.0K	EDGAR
2021-02-10	Turning Point Therapeutics, Inc. (TPTX) Delisted	Grant (A)	+2,136	$0	EDGAR
2020-07-14	Turning Point Therapeutics, Inc. (TPTX) Delisted	Grant (A)	+21,500	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.